Bpoc-Thr(tBu)-OSu

Bpoc-Thr(tBu)-OSu is a protected threonine derivative designed for peptide coupling, featuring a Bpoc (benzyloxycarbonyl-type) amino protecting group on the α-amine, a tert-butyl-protected side-chain hydroxyl on the threonine residue, and an activated N-hydroxysuccinimide ester (OSu) at the carboxylate. The molecule therefore combines a stereodefined amino acid core with orthogonal protection: the side-chain O-tBu can be managed under acid-labile conditions, while the Bpoc group can be removed using appropriate deprotection strategies compatible with peptide workflows. The OSu ester introduces high reactivity toward nucleophiles such as amines, enabling rapid formation of amide bonds under controlled coupling conditions. As a chiral, activated amino acid building block, Bpoc-Thr(tBu)-OSu supports downstream synthesis of protected peptide fragments and functional conjugates while maintaining the threonine stereocenter throughout peptide assembly.

1. Peptide Coupling

Bpoc-Thr(tBu)-OSu is applied in peptide synthesis as an activated threonine building block for amide bond formation, where the OSu ester reacts with peptide nucleophiles to generate the corresponding peptide linkage. The α-amino group is protected by the Bpoc group, allowing selective coupling at the carboxyl position without premature side reactions, while the threonine side-chain O-tBu maintains the hydroxyl as a non-nucleophilic handle during chain elongation. The stereodefined threonine backbone enables incorporation of the correct configuration into peptide sequences used for structure-activity relationship studies and fragment-based scaffold construction. The resulting protected peptide intermediates can be carried forward through iterative coupling and deprotection steps to access threonine-containing peptides and peptide analogs compatible with further functionalization.

2. Protected Amino Acid Synthesis

Bpoc-Thr(tBu)-OSu serves as a key intermediate in protected amino acid chemistry, combining an orthogonally protected side-chain hydroxyl with a carboxyl-activated leaving group for controlled downstream transformations. The Bpoc-protected α-amine and O-tBu-protected threonine hydroxyl provide protection-state control that supports sequential synthetic logic, including selective deprotection of the amino group for subsequent coupling and controlled exposure of the side-chain alcohol when required. The OSu functionality can be used to prepare defined amino acid derivatives that retain the threonine stereocenter for chiral intermediate supply in peptide building block preparation. The compound's design aligns with industrial and research workflows that require reproducible, protected chiral amino acid intermediates for fine chemical synthesis and peptide-manufacturing scale-up.

3. Bioconjugation Chemistry

Bpoc-Thr(tBu)-OSu is suitable for bioconjugation-oriented synthesis where OSu-activated carboxylates can react with primary amines on biomolecules or linkers to form stable amide conjugates. The threonine side-chain O-tBu protects the alcohol from interfering with conjugation chemistry, helping maintain chemoselectivity during amide formation and preserving the threonine residue as a defined stereochemical element in the conjugate. The Bpoc-protected amino functionality can be managed during conjugate assembly so that the activated ester chemistry proceeds without uncontrolled crosslinking from free amino groups. Downstream conjugates may be used as defined peptide-based constructs for chemical biology research, enabling controlled installation of threonine-containing motifs onto carrier proteins, scaffolds, or affinity tags.

4. Peptidomimetics And SAR Studies

Bpoc-Thr(tBu)-OSu is applied in peptidomimetic and medicinal chemistry research pipelines that require threonine incorporation with protected functional groups for later functional diversification. The threonine hydroxyl protected as O-tBu provides a handle for post-assembly transformations, such as conversion to alternative substituents or controlled deprotection to enable hydrogen-bonding or further derivatization in analog libraries. The OSu ester supports efficient coupling into peptide-like backbones, enabling rapid generation of defined analog series for structure-activity relationship studies where stereochemistry and side-chain functionality must be maintained. The protected amino acid nature of Bpoc-Thr(tBu)-OSu supports iterative library synthesis and subsequent analytical characterization of threonine-containing peptidomimetics.

5. Process Chemistry Intermediate

Bpoc-Thr(tBu)-OSu is relevant to process chemistry and specialty chemical production as a chiral, activated amino acid intermediate that can be integrated into manufacturing routes for protected peptide building blocks. The OSu ester form enables predictable nucleophilic acyl substitution chemistry, supporting scalable conversion into amide-containing intermediates while the Bpoc and O-tBu protections help reduce side reactions during upstream handling. The compound's stereodefined threonine core supports consistent stereochemical outcomes across batch synthesis, which is valuable for downstream peptide fragment preparation and controlled deprotection strategies. The resulting protected intermediates can feed into fine chemical synthesis of peptide reagents, peptide standards, and functional amino acid derivatives used across research and industrial chemistry.

1. Glucagonlike peptide 2 analogue teduglutide: stimulation of proliferation but reduction of differentiation in human Caco-2 intestinal epithelial cells

2. Proinsulin C-peptide and insulin: Limited pattern similarities of interest in inter-peptide interactions but no C-peptide effect on insulin and IGF-1 receptor signaling

3. Autoinhibition and phosphorylation-induced activation of phospholipase C-γ isozymes

4. Immune responses to peptides containing homocitrulline or citrulline in the DR4-transgenic mouse model of rheumatoid arthritis

5. Sex differences in oxidative stress level and antioxidative enzymes expression and activity in obese pre-diabetic elderly rats treated with metformin or liraglutide